Larotrectinib: Targeting DNA in cancer therapy

(Children's Hospital Los Angeles) FDA grants accelerated approval for Vitrakvi ® (larotrectinib) for the treatment of solid tumors. This is marks the second FDA-approved drug for cancers based on their genetic makeup as opposed to location in the body.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news